Cookies?
Library Header Image
LSE Research Online LSE Library Services

Adjuncts in the IVF laboratory: where is the evidence for ‘add-on’ interventions?

Harper, Joyce, Jackson, Emily ORCID: 0000-0002-2052-2776, Sermon, Karen, Aitken, Robert John, Harbottle, Stephen, Mocanu, Edgar, Hardarson, Thorir, Mathur, Raj, Viville, Stephane, Vail, Andy and Lundin, Kersti (2017) Adjuncts in the IVF laboratory: where is the evidence for ‘add-on’ interventions? Human Reproduction, 32 (3). pp. 485-491. ISSN 0268-1161

[img]
Preview
PDF - Accepted Version
Download (360kB) | Preview

Identification Number: 10.1093/humrep/dex004

Abstract

Globally, IVF patients are routinely offered and charged for a selection of adjunct treatments and tests or ‘add-ons’ that they are told may improve their chance of a live birth, despite there being no clinical evidence supporting the efficacy of the add on. Any new IVF technology claiming to improve live birth rates (LBR) should, in most cases, first be tested in an appropriate animal model, then in clinical trials, to ensure safety, and finally in a randomized controlled trial (RCT) to provide high quality evidence that the procedure is safe and effective. Only then should the technique be considered as ‘routine’ and only when applied to the similar patient population as those studied in the RCT. Even then, further paediatric and long-term follow up studies will need to be undertaken to examine the long-term safety of the procedure. Alarmingly, there are currently numerous examples where adjunct treatments are used in the absence of evidence-based medicine and often at an additional fee. In some cases, when RCTs have shown the technique to be ineffective, it is eventually withdrawn from the clinic. In this paper, we discuss some of the adjunct treatments currently being offered globally in IVF laboratories including embryo glue and adherence compounds, sperm DNA fragmentation, time lapse imaging, preimplantation genetic screening, mitochondria DNA load measurement and assisted hatching and examine the evidence for their safety and efficacy in increasing LBRs. We conclude that robust studies are needed to confirm the safety and efficacy of any adjunct treatment or test before they are offered routinely to IVF patients.

Item Type: Article
Official URL: https://humrep.oxfordjournals.org/
Additional Information: © 2017 The Authors
Divisions: Law
Subjects: R Medicine > R Medicine (General)
R Medicine > RG Gynecology and obstetrics
Date Deposited: 11 Jan 2017 12:57
Last Modified: 21 Nov 2024 23:18
URI: http://eprints.lse.ac.uk/id/eprint/68814

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics